ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0920

Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells

Elizabeth Morgan1, Bin Lin2, Sara alehashemi1, Adriana de Jesus1, Keith Kauffman3, Christopher Friend1, Farzana Bhuyan1, Kader Gedik1, Kat Uss1, Lauren Krausfeldt4, Jason Brenchley5, Zoran Gucev6, Kathryn Cook7, Vafa Mammadova8, Gulnara Nasrullayeva8, Mariana Correia Marques9, Abigail Bosk10, Brian Nolan11, Scott Canna12, Maude Tusseau13, Andrea Bohrer14, Katrin Mayer-Barber15, Timothy Moran16, Andrew Oler4, Daniel Barber3 and Raphaela Goldbach-Mansky1, 1Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, 2NIH, Bethesda, MD, 3T-Lymphocyte Biology Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, MD, 4Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, NIAID, NIH, Bethesda, MD, 5Barrier Immunity Section, Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, 6University Children's Hospital, Medical Faculty Skopje, Skopje, Macedonia, 7Akron Children’s Hospital, Akron, OH, 8Azerbaijan Medical University, Baku, Azerbaijan, 9Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 10Children’s National Hospital, Washington DC, 11Lurie Children’s Hospital, Chicago, 12Children's Hospital of Philadelphia, Philadelphia, PA, 13Hôpital Femme-Mère-Enfant, Bron, France, 14Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, MD, 15Inflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology (LCIM), Bethesda, MD, 16University of North Carolina School of Medicine, Chapel Hill, NC

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases, Inflammation, innate immunity, interferon, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0916–0933) Innate Immunity Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: NEMO-deleted 5 autoinflammatory syndrome (NEMO-NDAS) is an inflammatory disease caused by mosaic splice-site variants that lead to exon 5 skipping in IKBKG, encoding NEMO. Patients (pts) present with systemic inflammation, gdT-cells expansion, high serum IFNg, portal hypertension (PH) and porto-sinusoidal vascular disorders (PSVD). Here, we characterize the effect of exon 5-skipped NEMO on NFkB signaling in U937 cells, and assess intestinal barrier and gut microbiome dysregulation in the pathogenesis of PH and PSVD.

Methods: U937 cells with exon 5-skipped NEMO were created by CRISPR (MUT) and compared to wildtype U937 cells (WT). NFkB signaling, cell viability, p65 nuclear translocation, NEMO/IKKb colocalization, and mRNA transcription profiling were assessed in TNF-stimulated MUT and WT U937 cells. We assessed immune activation and target killing in pts’ PBMCs cocultured with WT and/or MUT U937s and quantified live U937 cells by flow cytometry. To characterize the gut-liver-axis, we analyzed intestinal fatty-acid-binding protein (I-FABP) concentrations in serum, and the stool microbiome (including virome), in NEMO-NDAS pts, inflammatory controls, and healthy household controls (HCs).

Results: Following TNF stimulation, nuclear translocation of p65 was significantly attenuated in MUT U937 cells consistent with impaired NFkB signaling. Additionally, increased susceptibility to TNF-induced cell death of MUT U937 cells was associated with a lack of upregulation of the anti-apoptotic genes BIRC3/cIAP2 and CFLAR/c-FLIP.To test the killing potential of expanded gd T cells in pts’ PBMCs, we cocultured pts’ PBMCs with WT or MUT U937 cells. While viability of WT U937 cells is not affected by the pts’ PBMC, mutant U937 cells are killed. When mixed WT and MUT U937s were cocultured with PBMCs, both WT and MUT U937s had decreased survival compared to PBMC-free conditions. Exploration of contributing cell types and pathomechanisms is ongoing.Liver-gut-axis evaluation suggested that NEMO-NDAS pts have increased IFABP serum levels compared to CANDLE pts and HCs, suggestive of increased intestinal permeability and impaired gut barrier function. Microbiome studies showed increased abundance of Faecalibacterium phages and a decrease in metabolic protective markers, which is consistent with previously reported data in liver disease.

Conclusion: Exon 5-skipping in NEMO impairs NFkB signaling, sensitizes U937 cells to TNF-induced cell death, and leads to U937 cell death in cocultures with PBMCs from NEMO-NDAS pts. We hypothesize that exon 5-skipped NEMO impairs gut epithelial cell function and leads to dysbiosis and increased microbial translocation that contribute to PH and PSVD in NEMO-NDAS. Whether impaired gut barrier and dysbiosis contribute to activation and expansion of gd T cells in NEMO-NDAS is under investigation.


Disclosures: E. Morgan: None; B. Lin: None; S. alehashemi: None; A. de Jesus: None; K. Kauffman: None; C. Friend: None; F. Bhuyan: None; K. Gedik: None; K. Uss: None; L. Krausfeldt: None; J. Brenchley: None; Z. Gucev: None; K. Cook: None; V. Mammadova: None; G. Nasrullayeva: None; M. Correia Marques: None; A. Bosk: None; B. Nolan: None; S. Canna: AB2Bio, 2, Bristol-Myers Squibb(BMS), 2, Novartis, 2, Simcha Therapeutics, 12, In-kind provision of a reagent, Sobi, 6; M. Tusseau: None; A. Bohrer: None; K. Mayer-Barber: None; T. Moran: None; A. Oler: None; D. Barber: None; R. Goldbach-Mansky: None.

To cite this abstract in AMA style:

Morgan E, Lin B, alehashemi S, de Jesus A, Kauffman K, Friend C, Bhuyan F, Gedik K, Uss K, Krausfeldt L, Brenchley J, Gucev Z, Cook K, Mammadova V, Nasrullayeva G, Correia Marques M, Bosk A, Nolan B, Canna S, Tusseau M, Bohrer A, Mayer-Barber K, Moran T, Oler A, Barber D, Goldbach-Mansky R. Functional Characterization of NEMO-NDAS Causing Variants in Patients’ PBMCs and in Wildtype and Mutant U937 Cells [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/functional-characterization-of-nemo-ndas-causing-variants-in-patients-pbmcs-and-in-wildtype-and-mutant-u937-cells/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/functional-characterization-of-nemo-ndas-causing-variants-in-patients-pbmcs-and-in-wildtype-and-mutant-u937-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology